These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 29408204)
1. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. Eliades P; Abraham BJ; Ji Z; Miller DM; Christensen CL; Kwiatkowski N; Kumar R; Njauw CN; Taylor M; Miao B; Zhang T; Wong KK; Gray NS; Young RA; Tsao H J Invest Dermatol; 2018 Jul; 138(7):1582-1590. PubMed ID: 29408204 [TBL] [Abstract][Full Text] [Related]
2. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer. Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040 [TBL] [Abstract][Full Text] [Related]
3. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor. Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612 [TBL] [Abstract][Full Text] [Related]
4. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer. Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037 [TBL] [Abstract][Full Text] [Related]
5. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists. Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587 [TBL] [Abstract][Full Text] [Related]
6. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538 [TBL] [Abstract][Full Text] [Related]
8. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway. Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425 [TBL] [Abstract][Full Text] [Related]
9. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263. Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555 [TBL] [Abstract][Full Text] [Related]
11. CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification. Hur JY; Kim HR; Lee JY; Park S; Hwang JA; Kim WS; Yoon S; Choi CM; Rho JK; Lee JC Cell Oncol (Dordr); 2019 Aug; 42(4):449-458. PubMed ID: 30838525 [TBL] [Abstract][Full Text] [Related]
12. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. Javelaud D; Alexaki VI; Pierrat MJ; Hoek KS; Dennler S; Van Kempen L; Bertolotto C; Ballotti R; Saule S; Delmas V; Mauviel A Pigment Cell Melanoma Res; 2011 Oct; 24(5):932-43. PubMed ID: 21801332 [TBL] [Abstract][Full Text] [Related]
13. Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. Wong RWJ; Ngoc PCT; Leong WZ; Yam AWY; Zhang T; Asamitsu K; Iida S; Okamoto T; Ueda R; Gray NS; Ishida T; Sanda T Blood; 2017 Nov; 130(21):2326-2338. PubMed ID: 28978570 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC. Ge H; Yao Y; Jiang Y; Wu X; Wang Y Oral Dis; 2022 Apr; 28(3):611-620. PubMed ID: 33503275 [TBL] [Abstract][Full Text] [Related]
15. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Cayrol F; Praditsuktavorn P; Fernando TM; Kwiatkowski N; Marullo R; Calvo-Vidal MN; Phillip J; Pera B; Yang SN; Takpradit K; Roman L; Gaudiano M; Crescenzo R; Ruan J; Inghirami G; Zhang T; Cremaschi G; Gray NS; Cerchietti L Nat Commun; 2017 Jan; 8():14290. PubMed ID: 28134252 [TBL] [Abstract][Full Text] [Related]
16. [Epigenetic regulation of gene expression in malignant melanoma]. Laurette P; Koludrovic D; Coassolo S; Davidson I Biol Aujourdhui; 2016; 210(4):283-295. PubMed ID: 28327285 [TBL] [Abstract][Full Text] [Related]
17. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639 [TBL] [Abstract][Full Text] [Related]
18. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142 [TBL] [Abstract][Full Text] [Related]
19. SOX5 is involved in balanced MITF regulation in human melanoma cells. Kordaß T; Weber CE; Oswald M; Ast V; Bernhardt M; Novak D; Utikal J; Eichmüller SB; König R BMC Med Genomics; 2016 Feb; 9():10. PubMed ID: 26927636 [TBL] [Abstract][Full Text] [Related]
20. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]